AxeroVision Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 1

AxeroVision General Information

Description

Developer of novel therapies intended to assist in the treatment of ophthalmic inflammatory diseases. The company's therapies are focused on dry eye diseases that address the underlying inflammatory processes, enabling patients to get more meaningful clinical benefits.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 5857 Owens Avenue
  • Suite 300
  • Carlsbad, CA 92008
  • United States
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • 5857 Owens Avenue
  • Suite 300
  • Carlsbad, CA 92008
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AxeroVision Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AxeroVision‘s full profile, request access.

Request a free trial

AxeroVision Patents

AxeroVision Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2024056898-A Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at ocular surface Active 21-Nov-2017
CA-3080166-A1 Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface Pending 21-Nov-2017
WO-2019104207-A2 Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface Inactive 21-Nov-2017
WO-2019104207-A3 Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface Inactive 21-Nov-2017
CA-2989522-A1 Pharmaceutical compositions and methods for treating ocular inflammatory conditions Active 08-Jul-2015 A61K31/445
To view AxeroVision’s complete patent history, request access »

AxeroVision FAQs

  • When was AxeroVision founded?

    AxeroVision was founded in 2016.

  • Where is AxeroVision headquartered?

    AxeroVision is headquartered in Carlsbad, CA.

  • What industry is AxeroVision in?

    AxeroVision’s primary industry is Drug Discovery.

  • Is AxeroVision a private or public company?

    AxeroVision is a Private company.

  • What is AxeroVision’s current revenue?

    The current revenue for AxeroVision is .

  • When was AxeroVision acquired?

    AxeroVision was acquired on 28-Jul-2023.

  • Who acquired AxeroVision?

    AxeroVision was acquired by CS Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process